Financing channel feed

The Covid-19 trans­genic cow an­ti­body start­up goes pub­lic in $325M SPAC merg­er

4 years ago

On the hunt for the next Mod­er­na, in­vestors have pumped 'plat­form plays' with cash. Can any­thing slow the run­away train?

4 years ago
In Focus

The dig­i­tal health field con­tin­ues to boom as Soft­Bank-backed start­up hits uni­corn sta­tus in SPAC re­verse merg­er

4 years ago
Deals

With a new $255M megaround in hand, Alex Zha­voronkov has big plans for In­sil­i­co. Are they fea­si­ble?

4 years ago
AI

LAG-3 con­tin­ues gen­er­at­ing heavy buzz as Aus­trali­a's Im­mutep locks down new funds

4 years ago

Hutchmed files for $600M+ IPO in Hong Kong as lead on­col­o­gy drug su­r­u­fa­tinib awaits FDA's good graces

4 years ago
China

An­oth­er four IPOs com­plete busy week as biotech raise con­tin­ues to match 2020's record pace

4 years ago

A re­place­ment for read­ing glass­es? An RA, Ver­sant-backed start­up thinks its eye­drops could solve far­sight­ed­ness

4 years ago
Startups

Rick Klaus­ner's crew of T cell spe­cial­ists wraps $425M IPO, hit­ting Nas­daq along­side Verve, Mol­e­c­u­lar Part­ners

4 years ago

A UK biotech looks to bring al­liance be­tween GSK, J&J, As­traZeneca, and top uni­ver­si­ties state­side with its first megaround

4 years ago

An Is­raeli biotech is look­ing to make its name in the jam-packed CD47 space. Is bi­func­tion­al­i­ty the an­swer?

4 years ago

A UK biotech looks to up­set the pre­clin­i­cal mod­el for liv­er drug de­vel­op­ment, and now it's gear­ing up for the clin­ic

4 years ago

Aus­tralian spin­out eyes the clin­ic with a pro­phy­lac­tic nasal spray for Covid-19

4 years ago

An­oth­er life sci­ences SPAC has popped up from a small biotech CEO with the help of Take­da, No­var­tis vet­er­ans

4 years ago

Af­ter a decade in the type 2 di­a­betes game, Fractyl Lab­o­ra­to­ries recharges with a fresh $100M and a new name

4 years ago

Michel Sade­lain puts his name and new cell en­gi­neer­ing tech be­hind 'ag­nos­tic' CAR-T start­up chas­ing epi­ge­net­ic anti­gens

4 years ago
Startups
Cell/Gene Tx

An­oth­er busy week for IPOs be­gins with an off-the shelf cell ther­a­py play­er sniff­ing around uni­corn sta­tus

4 years ago

Start­ing fresh in man­u­fac­tur­ing, For­bion start­up re­fu­els to steer next-gen gene ther­a­py ap­proach for ALS, Alzheimer's in­to clin­ic

4 years ago
Cell/Gene Tx

Just shy of its 1-year an­niver­sary, ra­dio­phar­ma­ceu­ti­cals plat­form play Rayze­Bio bags an­oth­er megaround

4 years ago

Soft­Bank, Cor­morant lead hefty $210M in­jec­tion for Umo­ja's three-in-one can­cer im­munother­a­py play

4 years ago

Go­ing af­ter the phe­nom­e­non of 're­gR­NA,' Rick Young's Camp4 se­cures a launch round to push two pro­grams for­ward

4 years ago
Startups

Swiss-based up­start march­es to­ward the clin­ic with a unique ap­proach to fi­bro­sis treat­ment

4 years ago

As Covid-19 shifts the world's at­ten­tion to biotech, Noubar Afeyan's Flag­ship builds $3.4B fund to fu­el new in­ven­tions. Here's the plan

4 years ago

The IPO 4-1-1: Four fil­ings, a pric­ing and a with­draw­al head­line this week's Nas­daq ac­tion as raise ap­proach­es $7.5B

4 years ago
First page Previous page 72737475767778 Next page Last page
A service from the Financial Times